Urokinase-Type Plasminogen Activator
"Urokinase-Type Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.
| Descriptor ID |
D014568
|
| MeSH Number(s) |
D08.811.277.656.300.760.910 D08.811.277.656.959.350.910 D12.776.124.125.662.884
|
| Concept/Terms |
Urokinase-Type Plasminogen Activator- Urokinase-Type Plasminogen Activator
- Urokinase Type Plasminogen Activator
- Plasminogen Activator, Urokinase-Type
- U-Plasminogen Activator
- U Plasminogen Activator
- U-PA
- Urinary Plasminogen Activator
- Urokinase
|
Below are MeSH descriptors whose meaning is more general than "Urokinase-Type Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Urokinase-Type Plasminogen Activator".
This graph shows the total number of publications written about "Urokinase-Type Plasminogen Activator" by people in this website by year, and whether "Urokinase-Type Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urokinase-Type Plasminogen Activator" by people in Profiles.
-
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Apr 01; 34(10):1134-50.
-
Meeker RB, Poulton W, Markovic-Plese S, Hall C, Robertson K. Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J Neurovirol. 2011 Jun; 17(3):258-73.
-
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20; 25(33):5287-312.
-
Graeven U, Fiedler W, Karpinski S, Ergün S, Kilic N, Rodeck U, Schmiegel W, Hossfeld DK. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol. 1999 Nov; 125(11):621-9.
-
Hartmann JR, McKeever LS, O'Neill WW, White CJ, Whitlow PL, Gilmore PS, Doorey AJ, Galichia JP, Enger EL. Recanalization of Chronically Occluded Aortocoronary Saphenous Vein Bypass Grafts With Long-Term, Low Dose Direct Infusion of Urokinase (ROBUST): a serial trial. J Am Coll Cardiol. 1996 Jan; 27(1):60-6.
-
Jensen PJ, Rodeck U. Autocrine/paracrine regulation of keratinocyte urokinase plasminogen activator through the TGF-alpha/EGF receptor. J Cell Physiol. 1993 May; 155(2):333-9.